SH1 Domain Autophosphorylation of P210 BCR/ABL is Required for Transformation but Not Growth Factor Independence

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 1993 Mar 1

PMID 8441409

Citations 34

Authors

A M Pendergast

M L Gishizky

M H Havlik

O N Witte

Affiliations

Soon will be listed here.

Abstract

P210 BCR/ABL is a chimeric oncogene implicated in the pathogenesis of chronic myelogenous leukemia. BCR sequences have been shown to be required for activation of the tyrosine kinase and transforming functions of BCR/ABL. In this work, we show that two other structural requirements for full transforming activity of P210 BCR/ABL include a functional tyrosine kinase and the presence of tyrosine 1294, a site of autophosphorylation within the tyrosine kinase domain. Replacement of tyrosine 1294 with phenylalanine (1294F) greatly diminishes the transforming activity of BCR/ABL without affecting the specific activity of the protein tyrosine kinase. Expression of an exogenous myc gene in fibroblasts partially complements the transforming capacity of mutant P210 BCR/ABL (1294F). Surprisingly, tyrosine 1294 is not required for efficient induction of growth factor-independence in hematopoietic cell lines by P210 BCR/ABL. These results suggest that autophosphorylation at tyrosine 1294 may be important for recognition and phosphorylation of cellular substrates in the pathway of transformation, but it is not critical for mediating the events which lead to growth factor independence.

Citing Articles

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.

Rauzan M, Chuah C, Ko T, Ong S PLoS One. 2017; 12(3):e0174107.

PMID: 28301600 PMC: 5354438. DOI: 10.1371/journal.pone.0174107.

The Philadelphia chromosome in leukemogenesis.

Kang Z, Liu Y, Xu L, Long Z, Huang D, Yang Y Chin J Cancer. 2016; 35:48.

PMID: 27233483 PMC: 4896164. DOI: 10.1186/s40880-016-0108-0.

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Lipka D, Wagner M, Dziadosz M, Schnoder T, Heidel F, Schemionek M PLoS One. 2012; 7(7):e40853.

PMID: 22815843 PMC: 3397954. DOI: 10.1371/journal.pone.0040853.

Molecular and cellular bases of chronic myeloid leukemia.

Chen Y, Peng C, Li D, Li S Protein Cell. 2011; 1(2):124-32.

PMID: 21203982 PMC: 4875160. DOI: 10.1007/s13238-010-0016-z.

BUB3 that dissociates from BUB1 activates caspase-independent mitotic death (CIMD).

Niikura Y, Ogi H, Kikuchi K, Kitagawa K Cell Death Differ. 2010; 17(6):1011-24.

PMID: 20057499 PMC: 2866768. DOI: 10.1038/cdd.2009.207.

References

Snyder M, Bishop J, Colby W, Levinson A . Phosphorylation of tyrosine-416 is not required for the transforming properties and kinase activity of pp60v-src. Cell. 1983; 32(3):891-901. DOI: 10.1016/0092-8674(83)90074-0. View

Muller A, Young J, Pendergast A, Pondel M, Landau N, Littman D . BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol. 1991; 11(4):1785-92. PMC: 359845. DOI: 10.1128/mcb.11.4.1785-1792.1991. View

Ellis C, Liu X, Anderson D, Abraham N, Veillette A, Pawson T . Tyrosine phosphorylation of GAP and GAP-associated proteins in lymphoid and fibroblast cells expressing lck. Oncogene. 1991; 6(6):895-901. View

Pendergast A, Muller A, Havlik M, Maru Y, Witte O . BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991; 66(1):161-71. DOI: 10.1016/0092-8674(91)90148-r. View

Metz T, Graf T . Fusion of the nuclear oncoproteins v-Myb and v-Ets is required for the leukemogenicity of E26 virus. Cell. 1991; 66(1):95-105. DOI: 10.1016/0092-8674(91)90142-l. View

Kakizuka A, Miller Jr W, Umesono K, Warrell Jr R, Frankel S, Murty V . Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991; 66(4):663-74. DOI: 10.1016/0092-8674(91)90112-c. View

de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A . The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991; 66(4):675-84. DOI: 10.1016/0092-8674(91)90113-d. View

Roussel M, Cleveland J, Shurtleff S, Sherr C . Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature. 1991; 353(6342):361-3. DOI: 10.1038/353361a0. View

Maru Y, Witte O . The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell. 1991; 67(3):459-68. DOI: 10.1016/0092-8674(91)90521-y. View

10.

Luo K, Hurley T, Sefton B . Cyanogen bromide cleavage and proteolytic peptide mapping of proteins immobilized to membranes. Methods Enzymol. 1991; 201:149-52. DOI: 10.1016/0076-6879(91)01014-s. View

11.

Goddard A, Borrow J, Freemont P, Solomon E . Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science. 1991; 254(5036):1371-4. DOI: 10.1126/science.1720570. View

12.

Reedijk M, Liu X, van der Geer P, Letwin K, Waterfield M, Hunter T . Tyr721 regulates specific binding of the CSF-1 receptor kinase insert to PI 3'-kinase SH2 domains: a model for SH2-mediated receptor-target interactions. EMBO J. 1992; 11(4):1365-72. PMC: 556585. DOI: 10.1002/j.1460-2075.1992.tb05181.x. View

13.

Kashishian A, Kazlauskas A, Cooper J . Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo. EMBO J. 1992; 11(4):1373-82. PMC: 556586. DOI: 10.1002/j.1460-2075.1992.tb05182.x. View

14.

Fantl W, Escobedo J, Martin G, Turck C, del Rosario M, McCormick F . Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell. 1992; 69(3):413-23. DOI: 10.1016/0092-8674(92)90444-h. View

15.

Peters K, Marie J, Wilson E, IVES H, Escobedo J, del Rosario M . Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature. 1992; 358(6388):678-81. DOI: 10.1038/358678a0. View

16.

Mohammadi M, Dionne C, Li W, Li N, Spivak T, Honegger A . Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature. 1992; 358(6388):681-4. DOI: 10.1038/358681a0. View

17.

Sawyers C, Callahan W, Witte O . Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992; 70(6):901-10. DOI: 10.1016/0092-8674(92)90241-4. View

18.

Muller A, Pendergast A, Havlik M, Puil L, Pawson T, Witte O . A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Mol Cell Biol. 1992; 12(11):5087-93. PMC: 360442. DOI: 10.1128/mcb.12.11.5087-5093.1992. View

19.

Pawson T, Gish G . SH2 and SH3 domains: from structure to function. Cell. 1992; 71(3):359-62. DOI: 10.1016/0092-8674(92)90504-6. View

20.

Groffen J, Stephenson J, Heisterkamp N, de Klein A, Bartram C, Grosveld G . Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984; 36(1):93-9. DOI: 10.1016/0092-8674(84)90077-1. View